360 related articles for article (PubMed ID: 26420336)
1. Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics.
Litau S; Niedermoser S; Vogler N; Roscher M; Schirrmacher R; Fricker G; Wängler B; Wängler C
Bioconjug Chem; 2015 Dec; 26(12):2350-9. PubMed ID: 26420336
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
3. Radiosynthesis and Preclinical Evaluation of
Maschauer S; Heilmann M; Wängler C; Schirrmacher R; Prante O
Bioconjug Chem; 2016 Nov; 27(11):2707-2714. PubMed ID: 27715017
[TBL] [Abstract][Full Text] [Related]
4. One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET).
Wängler C; Waser B; Alke A; Iovkova L; Buchholz HG; Niedermoser S; Jurkschat K; Fottner C; Bartenstein P; Schirrmacher R; Reubi JC; Wester HJ; Wängler B
Bioconjug Chem; 2010 Dec; 21(12):2289-96. PubMed ID: 21082773
[TBL] [Abstract][Full Text] [Related]
5. Radiosynthesis of [
Lindner S; Wängler C; Bailey JJ; Jurkschat K; Bartenstein P; Wängler B; Schirrmacher R
Nat Protoc; 2020 Dec; 15(12):3827-3843. PubMed ID: 33230332
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography.
Lindner S; Michler C; Leidner S; Rensch C; Wängler C; Schirrmacher R; Bartenstein P; Wängler B
Bioconjug Chem; 2014 Apr; 25(4):738-49. PubMed ID: 24666287
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.
Liu Z; Pourghiasian M; Bénard F; Pan J; Lin KS; Perrin DM
J Nucl Med; 2014 Sep; 55(9):1499-505. PubMed ID: 24970911
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFA
Cheng X; Hübner R; von Kiedrowski V; Fricker G; Schirrmacher R; Wängler C; Wängler B
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34200477
[TBL] [Abstract][Full Text] [Related]
10.
Gao F; Zhang Y; Chen M; Song Z; Dong R; Qiu S; Shen C; Huang X; Geng H; Cheng W; Hu J
Eur J Pharm Sci; 2024 Feb; 193():106671. PubMed ID: 38104907
[TBL] [Abstract][Full Text] [Related]
11. Microscale radiosynthesis, preclinical imaging and dosimetry study of [
Lisova K; Sergeev M; Evans-Axelsson S; Stuparu AD; Beykan S; Collins J; Jones J; Lassmann M; Herrmann K; Perrin D; Lee JT; Slavik R; van Dam RM
Nucl Med Biol; 2018 Jun; 61():36-44. PubMed ID: 29747035
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of a Bioorthogonal PET Tracer Candidate [
Otaru S; Niemikoski H; Sarparanta M; Airaksinen AJ
Mol Pharm; 2020 Aug; 17(8):3106-3115. PubMed ID: 32539414
[TBL] [Abstract][Full Text] [Related]
13. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
14. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
17. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography.
Schottelius M; Poethko T; Herz M; Reubi JC; Kessler H; Schwaiger M; Wester HJ
Clin Cancer Res; 2004 Jun; 10(11):3593-606. PubMed ID: 15173065
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of a dual sstr2 and integrin α
Liu B; Zhang Z; Wang H; Yao S
Bioorg Med Chem; 2019 Nov; 27(21):115094. PubMed ID: 31540828
[TBL] [Abstract][Full Text] [Related]
19. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
